Tumor antigen-sensitized DC vaccine and their sensitized T cells therapy(Sichuan University)

N/A

Report date: 2024/04/02 14:40:44

Base Information

Drug NameTumor antigen-sensitized DC vaccine and their sensitized T cells therapy(Sichuan University)
Drug Alias NameTumor antigen-sensitized DC vaccine and their sensitized T cells therapy(Sichuan University)Personalized Immune Cell Therapy(Sichuan University)OCDC vaccine(Sichuan University)NeoDC vaccine(Sichuan University)Neo-DCVac combined with ICIs (Sichuan University) +[9] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsUrinary Bladder NeoplasmsLung NeoplasmsColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesWest China Hospital Of Sichuan University
Inactive CompaniesSichuan University
Active IndicationsLung NeoplasmsColorectal NeoplasmsCarcinoma
Inactive IndicationsUrinary Bladder NeoplasmsEsophageal Squamous Cell CarcinomaMelanoma

Other Information

ATC CodeN/A
Related LinksN/A